Abstract
The aim of the study was to assess bone mineral density, bone metabolism markers, and vitamin D level in children with idiopathic nephrotic syndrome in the course of 1-year observation. Twenty five children with nephrotic syndrome aged 5–17 years were enrolled into the study. The median number of relapses was 6 (range 1–22). All patients were treated with prednisone and vitamin D (800 IU/day). Bone mineral density of total body (TB-BMD) and lumbar spine (L-BMD), evaluated by dual energy X-ray absorptiometry (DXA) expressed as Z-score, and serum calcium, phosphorus, parathormone (iPTH), alkaline phosphatase (ALP), bone alkaline phosphatase (BAP), osteocalcin (OC), albumin, creatinine, 25(OH)D3, 1,25(OH)2D3 and urine calcium/creatinine ratio (uCa/Cr) were evaluated at the enrollment visit and after 1 year of therapy. After 1 year significant decreases of TB-BMD Z-score (from −0.24 ± 1.34 to −0.74 ± 1.31, p < 0.05) and 25(OH)D3 serum level (from 31.7 ± 16.3 to 23.7 ± 9.3; p < 0.05) were observed. No other appreciable differences were found. At the study onset, negative correlations were found between L-BMD Z-score and serum ALP, BAP, and phosphorus and between TB-BMD Z-score and urine uCa/Cr. After 1 year, L-BMD Z-score correlated negatively with serum BAP and OC, and positively with serum 25(OH)D3. Multivariate analysis showed that BAP was the strongest predictor of L-BMD Z-score (beta = −0.49; p < 0.05). We conclude that children with nephrotic syndrome treated with corticosteroids are at risk of bone mass loss. Serum BAP concentration seems to be a good indicator of spongy bone metabolism in these children, who should be supplemented with vitamin D in an adjustable dose, possibly higher than 800 IU/24 h to prevent osteopenia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ambroszkiewicz J, Gajewska J, Laskowska-Klita T (2002) Serum osteocalcin and bone alkaline phosphatase in relation to age and gender. Med Wieku Rozwoj 6:257–265
Arabi A, Baddoura R, El-Rassi R, El-Hajj Fuleihan G (2012) PTH level but not 25 (OH) vitamin D level predicts bone loss rates in the elderly. Osteoporos Int 64:971–980
Bak M, Serdaroglu E, Guclu R (2006) Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatr Nephrol 21:350–354
Biyikli NK, Emre S, Sirin A, Bilge I (2004) Biochemical bone markers in nephrotic children. Pediatr Nephrol 19:869–873
Canalis E, Pereira RC, Delany AM (2002) Effects of glucocorticoids on the skeleton. J Pediatr Endocrinol Metab 15(Suppl 5):1341–1345
Canalis E, Mazzioti G, Giustina A, Bilezikian JP (2007) Glucocorticoid–induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328
Cavalier E, Rozet E, Carlisi A, Bekaert AC, Rousselle O, Hubert P, Chapelle JP, Delanaye P (2010) Analytical validation of serum bone alkaline phosphatase (BAP OSTASE) on Liaison. Clin Chem Lab Med 48:67–72
Csakvary V, Puskas T, Oroszlan G, Lakatos P, Kalman B, Kovacs GL, Toldy E (2013) Hormonal and biochemical parameters correlated with bone densitometric markers in prepubertal Hungarian children. Bone 54:106–112
Demiaux B, Arlot ME, Chapuy MC, Meunier PJ, Delmas PD (1992) Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab 74:1146–1151
Dobrzańska A, Charzewska J, Chlebna-Sokół D, Chybicka A, Czech-Kowalska J, Helwich E, Imiela JR, Karczmarewicz E, Książyk JB, Lewiński A, Lorenc RS, Lukas W, Łukaszkiewicz J, Marcinowska-Suchowierska E, Milanowski A, Milewicz A, Płudowski P, Pronicka E, Radowicki S, Ryżko J, Socha J, Szczapa J, Weker H (2010) Prophylaxis of vitamin D deficiency – Polish recommendations 2009. Pol Merkur Lekarski 28:130–133
Eastell R, Hannon RA (2008) Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 67:157–162
Feber J, Gaboury I, Ni A, Alos N, Arora S, Bell L, Blydt-Hansen T, Clarson C, Filler G, Hay J, Hebert D, Lentle B, Matzinger M, Midgley J, Moher D, Pinsk M, Rauch F, Rodd C, Shenouda N, Siminoski K, Ward LM, Canadian STOPP Consortium (2012) Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. Osteoporos Int 23:751–760
Freundlich M, Jofe M, Goodman WG, Salusky IB (2004) Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol 19:400–407
Fujiyoshi A, Polgreen LE, Hurley DL, Gross MD, Sidney S, Jacobs DR Jr (2013) A cross-sectional association between bone mineral density and parathyroid hormone and other biomarkers in community-dwelling young adults: the CARDIA study. J Clin Endocrinol Metab 98:4038–4046
Gulati S, Godbole M, Singh U, Gulati K, Srivastava A (2003) Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? Am J Kidney Dis 41:1163–1169
Gulati S, Sharma RK, Gulati K, Singh U, Srivastava A (2005) Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements. Nephrol Dial Transplant 20:1598–1603
Hidalgo AA, Trump DL, Johnson CS (2010) Glucocorti-coid regulation of the vitamin D receptor. J Steroid Biochem Mol Biol 121:372–375
Hoppe B, Kemper MJ (2010) Diagnostic examination of the child with urolithiasis or nephrocalcinosis. Pediatr Nephrol 25:403–413
ISKDC – A report of the International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 13:159–165
KDIGO Clinical Practice Guideline for Glomerulonephritis (2012) Chapter 3: steroid-sensitive nephrotic syndrome in children. Kidney Int Supp 2:163–171
Khaw KT, Sneyd MJ, Compston J (1992) Bone density parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women. Br Med J 305:273–277
Koşan C, Ayar G, Orbak Z (2012) Effects of steroid treatment on bone mineral metabolism in children with glucocorticoid-sensitive nephrotic syndrome. West Indian Med J 61:627–630
Kotowicz MA, Hall S, Hunder GG, Cedel SL, Mann KG, Riggs BL (1990) Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders. Arthritis Rheum 33:1487–1492
Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA (2004) Long –term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 351:868–875
Lettgen B, Jeken C, Reiners C (1994) Influence of steroids medication on bone mineral density in children with nephrotic syndrome. Pediatr Nephrol 8:667–670
Mishra OP, Meena SK, Singh SK, Prasad R, Mishra RN (2009) Bone mineral density in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 76:1237–1239
Rogers A, Hannon RA, Eastell R (2000) Biochemical markers as predictors of rates of bone loss after menopause. J Bone Mineral Res 15:1398–1404
Ross PD, Knowlton W (1998) Rapid bone loss is associated with increased levels of biochemical markers. J Bone Mineral Res 13:297–302
Saag KG (2003) Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 32:135–157
Sasaki N, Kusano E, And oY, Nemoto J, Iimura O, Ito C, Takeda S, Yano K, Tsuda E, Asano Y (2002) Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 30:653–658
Zaniew M, Jarmolinski T (2012) Vitamin D status and bone density in steroid-treated children with glomerulopathies: effect of cholecalciferol and calcium supplementation. Adv Med Sci 57:88–93
Conflicts of Interest
The authors declare no conflict of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Pańczyk-Tomaszewska, M. et al. (2014). Markers of Bone Metabolism in Children with Nephrotic Syndrome Treated with Corticosteroids. In: Pokorski, M. (eds) Body Metabolism and Exercise. Advances in Experimental Medicine and Biology(), vol 840. Springer, Cham. https://doi.org/10.1007/5584_2014_87
Download citation
DOI: https://doi.org/10.1007/5584_2014_87
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10249-8
Online ISBN: 978-3-319-10250-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)